Human Recombinant GPRC5D, Nanodisc protein, Biotin Conjugated, His Tag (V2LY-0526-LY4399)

Name: Human Recombinant GPRC5D, Nanodisc protein, Biotin Conjugated, His Tag
SKU: V2LY-0526-LY4399
Rating: 5 (1 reviews)

See all GPRC5D antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host

HEK293 Cells

Protein Species

Human

Tag

His Tag

Protein Construction

This product is Human Recombinant GPRC5D, Nanodisc protein, Biotin Conjugated, His Tag consist of Amino Acid: 1-268 and predicts a molecular mass of 33.78 kDa.

Molecule Mass

33.78 kDa

Conjugates

Biotin

Sequence

Amino Acid: 1-268

Species

Human

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity

≥80% as determined by SDS-PAGE.

Endotoxin

Please contact us for more information.

Format

Liquid

Buffer

PBS

Preservative

None

Storage

Samples are stable for up to twelve months from date of receipt at -70°C. Store it under sterile conditions at -70°C or lower. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

More Infomation

Target

Full Name

G protein-coupled receptor class C group 5 member D

Cellular Location

Cell membrane

Topology

Extracellular: 1-27
Helical: 28-48
Cytoplasmic: 49-63
Helical: 64-84
Extracellular: 85-93
Helical: 94-114
Cytoplasmic: 115-123
Helical: 124-144
Extracellular: 145-167
Helical: 168-188
Cytoplasmic: 189-204
Helical: 205-225
Extracellular: 226-239
Helical: 240-260
Cytoplasmic: 261-345

Zhang, M., Wei, G., Zhou, L., Zhou, J., Chen, S., Zhang, W., ... & Huang, H. (2023). GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. The Lancet Haematology, 10(2), e107-e116.

Nath, K., Costa, B. A., & Mailankody, S. (2023). GPRC5D as a novel immunotherapeutic target in multiple myeloma. Nature Reviews Clinical Oncology, 1-2.

Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J., ... & Smith, E. L. (2022). GPRC5D-targeted CAR T cells for myeloma. New England Journal of Medicine, 387(13), 1196-1206.

Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W., Rodríguez-Otero, P., ... & Krishnan, A. (2022). Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. New England Journal of Medicine, 387(24), 2232-2244.

Berdeja, J. G., Krishnan, A. Y., Oriol, A., van de Donk, N. W., Rodríguez-Otero, P., Askari, E., ... & Chari, A. (2021). Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)× CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

Mailankody, S., Diamonte, C., Fitzgerald, L., Kane, P., Wang, X., Sikder, D. S., ... & Smith, E. L. (2021). Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma. Blood, 138, 827.

Chari, A., Berdeja, J. G., Oriol, A., van de Donk, N. W., Rodriguez, P., Askari, E., ... & Krishnan, A. (2020). A phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and/or refractory multiple myeloma (RRMM). Blood, 136, 40-41.

Fernández de Larrea, C., Staehr, M., Lopez, A. V., Ng, K. Y., Chen, Y., Godfrey, W. D., ... & Smith, E. L. (2020). Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple MyelomaAddressing BCMA Escape with Dual-Targeted CAR T-cell Therapy. Blood Cancer Discovery, 1(2), 146-154.

Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., ... & Brentjens, R. J. (2019). GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science translational medicine, 11(485), eaau7746.

Kodama, T., Kochi, Y., Nakai, W., Mizuno, H., Baba, T., Habu, K., ... & Akashi, K. (2019). Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple MyelomaAnti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody. Molecular cancer therapeutics, 18(9), 1555-1564.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human Recombinant GPRC5D, Nanodisc protein, Biotin Conjugated, His Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Alternative Versions

Human Recombinant GPRC5D-VLP protein (CAT#: V2LY-0526-LY189)

Human Recombinant GPRC5D-VLP protein, Biotin Conjugated, (CAT#: V2LY-0526-LY190)

Human Recombinant GPRC5D-VLP protein, Fluorescent Conjugated, (CAT#: V2LY-0526-LY4400)

Mouse Recombinant GPRC5D (Nanodisc) protein, His Tag (CAT#: V2LY-0526-LY8373)

Related Products

Human Anti-GPRC5D Recombinant Antibody (CBLG1-1653) (CAT#: V2LY-0226-LY928)

Human Recombinant GPRC5D-VLP protein, Fluorescent Conjugated, (CAT#: V2LY-0526-LY4400)

Human Recombinant GPRC5D-VLP protein, Biotin Conjugated, (CAT#: V2LY-0526-LY190)

Rabbit Anti-GPRC5D Recombinant Antibody (EG1415) (CAT#: V2LY-0226-LY929)

Human Anti-GPRC5D Recombinant Antibody (CBLG1-208) (CAT#: CBMAB-G0732-LY)

Human Anti-GPRC5D Recombinant Antibody (CBLG1-1652) (CAT#: CBMAB-G4690-LY)

Mouse Anti-GPRC5D Recombinant Antibody (CBLG1-207) (CAT#: V2LY-0226-LY924)

Mouse Recombinant GPRC5D (Nanodisc) protein, His Tag (CAT#: V2LY-0526-LY8373)

Mouse Anti-GPRC5D Recombinant Antibody (CBFYH-0465) (CAT#: CBMAB-H1336-FY)

Human Anti-GPRC5D Recombinant Antibody (
3D4) (CAT#: V2LY-0725-LY1431)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry